Latest genotype Stories

BEERSE, Belgium, October 16, 2012 /PRNewswire/ -- NOT INTENDED FOR US JOURNALISTS - OPTIMIZE study results to be presented in late-breaking poster presentation at the American Association for the Study of Liver Diseases (AASLD) 2012 show non-inferior sustained virological response (SVR12) rates in previously untreated genotype-1 patients receiving an INCIVO(R) (telaprevir) based regimen twice-daily versus...

BOSTON, Oct. 16, 2012 /PRNewswire/ -- Janssen Research & Development Ireland (Janssen) will present new data on simeprevir (TMC435), an investigational protease inhibitor, in hepatitis C (HCV) patients at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which takes place November 9 to 13 in Boston. "We are pleased that these data have been selected for presentation at the AASLD annual meeting," said Wim Parys, Head of Infectious Diseases,...

BEDFORD, Mass., Oct. 16, 2012 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system. Hologic's APTIMA HPV 16 18/45 Genotype Assay is...

ABBOTT PARK Ill., Oct. 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C (HCV). Initial results show sustained virological response at 12 weeks post treatment (SVR12) in 99 percent of treatment-naive (n=77) and 93 percent of null responders (n=41) for genotype 1 (GT1) HCV patients taking a combination of ABT-450/r, ABT-267, ABT-333 and ribavirin...

The novel Natural Sciences Bibliographic Web Portal aims to provide comprehensive bibliographic information on the basic and applied life, earth and health sciences. The site has now published over 1,000,000 references and has included the two new sections Genetic and Genotype. While the publishers target to publish a total of over 21 million references until 2014, the site currently contains over 1,006,000 posts, increasing by about 10,000 items every day. References contain a minimum of...

RIDGEFIELD, Conn., Oct. 1, 2012 /PRNewswire/ -- New data from Boehringer Ingelheim's hepatitis C virus (HCV) clinical development program, HCVerso(TM),( )have been accepted for presentation at the 63(rd) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 9 - 13 in Boston, MA. Results from all arms of SOUND-C2, a Phase 2b trial evaluating an investigational interferon-free HCV treatment, along with other analyses of the trial...

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the two most recent hepatitis c (HCV) infected patients to receive Hemopurifier® therapy in combination with peginterferon+ribavirin (PR) drug therapy achieved undetectable viral load at day-7, which represents a significant clinical milestone in...

STOCKHOLM, Sweden, June 29, 2012 /PRNewswire/ -- - The phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naive or previous null responder patients with HCV genotype 1a and 1b - The study will include approx. 180 patients and will evaluate a combination of TMC435 and daclatasvir, with or without Ribavirin, in four different cohorts for 12 or 24 weeks of treatment...

FRAMINGHAM, Mass., May 30, 2012 /PRNewswire/ -- Boston Heart Diagnostics (BHD) announced today the commercial launch of the Statin Induced Myopathy (SLCO1B1) Genotype test licensed from the University of Oxford's technology commercialization company Isis Innovation. This adds to the company's IP portfolio and suite of cardiovascular disease (CVD)-focused tests that are designed to improve outcomes for patients and save health dollars by tailoring a therapeutic regimen to the patient's...

SAN DIEGO, May 8, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, reported today that the presence of Hepatitis C virus (HCV) is currently undetectable in all infected patients that have been treated with the Aethlon Hemopurifier® in combination with peginterferon+ribavirin (PR) drug therapy and monitored for at least ninety days....